Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Gynecology | Nursing | Surgery | Institutional

Back to Journal Articles

FDA Adds Boxed Warning Requirement to Essure Device

Last Updated: February 29, 2016.

A new boxed warning is needed on the Essure implantable birth control device, the U.S. Food and Drug Administration said in a guidance released Monday. The FDA also said Essure maker Bayer needs to conduct a study to assess the "risks of the device in a real-world environment."

MONDAY, Feb. 29, 2016 (HealthDay News) -- A new boxed warning is needed on the Essure implantable birth control device, the U.S. Food and Drug Administration said in a guidance released Monday. The FDA also said Essure maker Bayer needs to conduct a study to assess the "risks of the device in a real-world environment."

"The FDA will use the results of (the Bayer) study to determine what, if any, further actions related to Essure are needed to protect public health," the agency said in a news release. In addition, the FDA wants patients and physicians to sign a checklist before the device is implanted. It would include agreeing to a test three months after Essure is implanted to assess if it is in the correct location and functioning properly, CNN reported. Patients are already advised to have a check-up three months after receiving the device, but some don't follow through.

Between November 2002 and May 2015, more than 5,000 women filed complaints with the FDA about Essure. Problems include unplanned pregnancies, stillbirths, severe pain, and bleeding, CNN reported.

In September, the FDA held a hearing about Essure and heard from women who filed complaints, health care providers and Bayer officials. There is now a 60-day comment period for the public and industry to give feedback on the guidance, CNN reported.

More Information


Previous: Car Crash Risk May Nearly Double in Patients With Syncope Next: February 2016 Briefing - Allergy

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: